Circadian changes direction
Thursday, 12 June, 2008
Australian biotechnology firm Circadian Technologies (ASX: CIR) is restructuring and plans to evolve from a biotech incubator to a drug development company which will specialise in cancer treatments.
Circadian has appointed a product development review group, which includes both the former head of development and the former project team leader from US biotech Amgen.
The group will oversee the company's commercialisation of cancer treatment drugs based on its VEGF inhibitors, developed by subsidiary Vegenics.
Heart implant brings hope to refractory angina patients
The coronary sinus reducer is understood to redistribute blood flow within the wall of the heart,...
Researchers genetically engineer snake antivenom
An international team of researchers has used genetic engineering to create so-called...
Common medications linked to adverse breast cancer outcomes
An international study has found concerning evidence about the impact of a range of common...
